Arkolith/Insider Trading/BMRN/Form 4

Mueller Brian

EVP, Chief Financial OfficerBIOMARIN PHARMACEUTICAL INC (BMRN) · full profile →Form 4 · filed Mar 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 17, 2025Grant(A)17K—$0100K
Mar 14, 2025Tax withholding(F)18K$69.44$1.3M83K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 17, 2025Grant(A)39K—$039K

Transaction Codes

A
Grant / award
F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001048477-25-000029) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML